Journal of Liver Cancer

Duck Joo Choi

4 Articles

A Case of Successful Treatment by Radiofrequency Ablation for Pulmonary Metastasis of Hepatocellular Carcinoma: Jae Chan Park, Yun Soo Kim, Young Kul Jung, Myung Hee Kang, Oh Sang Kwon, Duck Joo Choi, Yang Suh Ku, Ju Hyun Kim; Journal of the Korean Liver Cancer Study Group. 2013;13(1):51-56. Published online February 28, 2013; DOI: https://doi.org/10.17998/jlc.13.1.51

Abstract PDF: Surgical resection or liver transplantation is a main curative modality for hepatocellular carcinoma (HCC). But nowadays local ablation therapy is being accepted as a useful option for local control therapy for HCC. Here we present a case of 59 years old male with hepatitis B virus related liver cirrhosis, who underwent surgery for HCC at S6 two years ago. He had received percutaneous ethanol injection (PEI), radiofrequency ablation (RFA) and multiple sessions of transarterial chemoembolization (TACE) for intrahepatic recurrences of HCC after surgery. A small radio-opaque lesion occurred at the left upper lobe of lung. Metastatic HCC was confirmed by CT-guided percutaneous needle core biopsy. CT-guided RFA for pulmonary metastasis was performed. Now it is been 11 months after the treatment without any recurrence.

Management of Cirrhotic Complications in Hepatocellular Carcinoma: Portal Hypertension, Ascites, and Variceal Beeding: Young Kul Jung, Duck Joo Choi; Journal of the Korean Liver Cancer Study Group. 2012;12(2):85-87. Published online September 30, 2012

Abstract PDF: Hepatocellular carcinoma (HCC) causes approximately one million deaths every year. Due to advanced stage at diagnosis, HCC carries a five-year survival rate of less than 5%, if diagnosed with unresectable disease. And also HCC is responsible for significant morbidity and mortality in cirrhosis. It leads to decompensation of cirrhosis and is the cause of death in up to 25% of cirrhotic patients. The purpose of this article is to provide an overview of the complexity in complication management of patients with terminal stage of HCC. The occurrence of complications in HCC patients is common, and includes portal hypertension, ascites, and variceal bleedings. Because of the limitations in the efficacy of current treatment options for terminal stage HCC, complication management is a key to preserving physical functioning and quality of life in these patients. Until now, diuretics remain the gold standard in management of ascites in cancer patients, and endoscopic treatment and vasoconstrictor are good choice for acute variceal bleedings. In several studies, sorafenib showed a potential as therapeutics for portal hypertension in patients with advanced HCC.

A Case of Small Hepatocellular Carcinoma Less Than 1 cm: Yun Jeong Jo, Young Kul Jung, Dong Hae Chung, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Ju Hyun Kim; Journal of the Korean Liver Cancer Study Group. 2012;12(1):42-46. Published online February 28, 2012

Abstract PDF: Hepatocellular carcinoma (HCC) is one of the most important causes of cancer death in South Korea. Approximately two thirds of the patients are diagnosed in the advanced stage with multiple metastasis and underlying liver dysfunction, so they are not suitable to undergo curative resection. Small HCC has no consensus about diagnostic criteria but became known early stage HCC that means good prognosis. Cases of small HCC have been increasing with the progress of diagnostic methods. We experienced a case of incidentally found small HCC less than 1 cm from liver cirrhosis by liver dynamic imaging, so reported it.

A Case of Improvement of Hypoglycemia by Sorafenib in Hepatocellular Carcinoma: Kwang Il Ko, Young Kul Jung, Jungsuk An, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Ju Hyun Kim; Journal of the Korean Liver Cancer Study Group. 2012;12(1):47-50. Published online February 28, 2012

Abstract PDF: The prevalence of hypoglycemia in hepatocellular carcinoma (HCC) ranged from 4 to 27%. The causes of hypoglycemia in HCC are two type. Type A is a poorly differentiated tumor with mild to moderate severity of hypoglycemia that occurs in the late stage of the disease. The less common type B tumor is a well-differentiated slow growing tumor in which severe hypoglycemia occurs in early stages of the disease. We reported a case of improvement of hypoglycemia due to HCC by sorafenib.